Clearmind Medicine Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CMND Nasdaq 2830 www.clearmindmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearmind Medicine Inc.

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - Aug 6th, 2026 6:00 am
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company - Aug 3rd, 2026 6:02 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Aug 2nd, 2026 4:26 pm
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial - Jul 30th, 2026 6:30 am
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - Jul 28th, 2026 5:47 am
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market - Jul 20th, 2026 5:55 am
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - Jul 17th, 2026 5:32 am
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Jul 16th, 2026 7:30 am
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Jul 13th, 2026 6:17 am
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative - Jul 10th, 2026 6:32 am
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI - Jul 7th, 2026 5:42 am
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength - Jun 29th, 2026 5:55 am
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial - Jun 22nd, 2026 6:07 am
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators - Jun 18th, 2026 5:55 am
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial - Jun 16th, 2026 5:32 am
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar - Jun 5th, 2026 5:32 am
Why Did CMND Stock Jump 40% Today? - May 29th, 2026 9:04 am
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment - May 29th, 2026 6:32 am
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts - May 26th, 2026 6:25 am
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - May 21st, 2026 4:49 am